Bulimia Nervosa Market Research Report Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL BULIMIA NERVOSA MARKET, BY DISORDER TYPE

6.1. Overview

6.2. Purging

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Non-Purging

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL BULIMIA NERVOSA MARKET, BY DRUG TYPE

7.1. Overview

7.2. Antidepressants

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Antipsychotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION

8.1. Overview

8.2. Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Intravenous

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL BULIMIA NERVOSA MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Homecare Settings

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Specialty Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL BULIMIA NERVOSA MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategies in the Global Bulimia Nervosa Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Bulimia Nervosa Market

11.7. Key Developments and Growth Strategies

11.7.1. Product Launch/Service Deployment

11.7.2. Mergers and Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix & Market Ratio

11.8.1. Sales & Operating Income 2020

11.8.2. Major Players R&D Expenditure 2020

11.9. Major Players Capital Market Ratio

12. COMPANY PROFILES

12.1. Allergan, Inc.

12.1.1. Company Overview

12.1.2. Product Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Eli Lilly and Company

12.2.1. Company Overview

12.2.2. Product Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. AstraZeneca

12.3.1. Company Overview

12.3.2. Product Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Bristol-Myers Squibb Company

12.4.1. Company Overview

12.4.2. Product Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. GlaxoSmithKline plc

12.5.1. Company Overview

12.5.2. Product Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Pfizer Inc.

12.6.1. Company Overview

12.6.2. Product Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Johnson & Johnson Services, Inc.

12.7.1. Company Overview

12.7.2. Product Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Dr. Reddy’s Laboratories Limited

12.8.1. Company Overview

12.8.2. Product Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Lupin Pharmaceuticals, Inc.

12.9.1. Company Overview

12.9.2. Product Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Aurobindo Pharma

12.10.1. Company Overview

12.10.2. Product Overview

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. Zydus Cadila

12.11.1. Company Overview

12.11.2. Product Overview

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Apotex Inc.

12.12.1. Company Overview

12.12.2. Product Overview

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. Teva Pharmaceutical Industries Ltd

12.13.1. Company Overview

12.13.2. Product Overview

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. Sun Pharmaceutical Industries Ltd

12.14.1. Company Overview

12.14.2. Product Overview

12.14.3. Financial Overview

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. Others

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BULIMIA NERVOSA MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL BULIMIA NERVOSA MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 7 GLOBAL BULIMIA NERVOSA MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 10 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 11 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 US: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 13 US: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 14 US: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 15 US: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 CANADA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 17 CANADA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 18 CANADA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 19 CANADA: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 21 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 22 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 23 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24 EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 25 EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 26 EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 27 EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 29 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 30 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 31 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 33 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 34 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 35 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2020-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BULIMIA NERVOSA MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BULIMIA NERVOSA MARKET

FIGURE 4 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY DISORDER TYPE, 2020 (%)

FIGURE 5 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY DRUG TYPE, 2020 (%)

FIGURE 6 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2020 (%)

FIGURE 7 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY END USER, 2020 (%)

FIGURE 8 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: BULIMIA NERVOSA MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: BULIMIA NERVOSA MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL BULIMIA NERVOSA MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ALLERGAN, INC..: KEY FINANCIALS

FIGURE 16 ALLERGAN, INC.: SEGMENTAL REVENUE

FIGURE 17 ALLERGAN, INC.: REGIONAL REVENUE

FIGURE 18 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 19 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 20 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 21 ASTRAZENECA: KEY FINANCIALS

FIGURE 22 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 23 ASTRAZENECA: REGIONAL REVENUE

FIGURE 24 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 27 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 28 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 29 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 30 PFIZER INC.: KEY FINANCIALS

FIGURE 31 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 32 PFIZER INC.: REGIONAL REVENUE

FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 36 DR. REDDY’S LABORATORIES LIMITED: KEY FINANCIALS

FIGURE 37 DR. REDDY’S LABORATORIES LIMITED: SEGMENTAL REVENUE

FIGURE 38 DR. REDDY’S LABORATORIES LIMITED: REGIONAL REVENUE

FIGURE 39 LUPIN PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 40 LUPIN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 41 LUPIN PHARMACEUTICALS, INC.: REGIONAL REVENUE

FIGURE 42 AUROBINDO PHARMA: KEY FINANCIALS

FIGURE 43 AUROBINDO PHARMA: SEGMENTAL REVENUE

FIGURE 44 AUROBINDO PHARMA: REGIONAL REVENUE

FIGURE 45 ZYDUS CADILA: KEY FINANCIALS

FIGURE 46 ZYDUS CADILA: SEGMENTAL REVENUE

FIGURE 47 ZYDUS CADILA: REGIONAL REVENUE

FIGURE 48 APOTEX INC.: KEY FINANCIALS

FIGURE 49 APOTEX INC.: SEGMENTAL REVENUE

FIGURE 50 APOTEX INC.: REGIONAL REVENUE

FIGURE 51 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 52 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE

FIGURE 54 SUN PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 55 SUN PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE